3 Promising Biotech Stocks with Upcoming Catalysts
Source: Tom Meyer, Wall St. Cheat Sheet  (11/4/13)
"Biotechnology stocks are some of the most volatile investments around. They are hard to analyze because, unlike almost all other stocks, the fundamentals aren't typically as important as the potential. And the potential is usually based on upcoming catalysts that the company will face." More >

2013 Biotech Watchlist Update: Companies Climb and Crumble on Catalysts
Source: George S. Mack of The Life Sciences Report   (10/31/13)
The Life Sciences Report's Biotech Watchlist, introduced in January 2013, is composed of 17 companies that industry analysts felt showed promise for the coming year—companies with productive pipelines, good management and stock-moving catalysts on the horizon. The new year presented legitimate prospects for portfolio growth and, indeed, that has been the case. In this update, we summarize the current status of Watchlist companies and introduce our Portfolio Tracker, showing the status of each company in real time. More >

Categorizing LifeSci Investments + 2 Niche Market Picks
Source: Brian Wilson, BioMedReports   (10/28/13)
"This is not to say that investors should necessarily avoid small or medium-sized clinical life science companies. The high risk comes with a high potential for return, although investors will probably have to spend a lot more time with their due diligence. Also required is a strong stomach for the volatility of these stocks." More >

This Biotechnology Platform Could Save Millions of Lives: Patrick Cox
Source: George S. Mack of The Life Sciences Report  (10/24/13)
Patrick Cox, editor of the brand-new publication Transformational Technology Alert, is acutely aware of how transformational technology platforms can enable efficiencies and improve scale a la Moore's Law. A sweeping new synthetic vaccine platform that poses infinite possibilities for researchers and could produce novel preventive and therapeutic drugs is a quintessential example. In this interview with The Life Sciences Report, Cox delivers a single name that holds the potential to save lives on a mass scale, cheaply and efficiently, in both the developed and developing world—and deliver health and wealth to investors' portfolios as well. More >

4 Pharma Stocks Could Deliver Earnings Surprises
Source: Zacks Equity Research  (10/22/13)
"New products are expected to support top line going forward. This, along with increased pipeline visibility and smart utilization of cash, should increase confidence in the sector." More >

A Compulsion for Brain Science: Zack Lynch
Source: George S. Mack of The Life Sciences Report  (10/17/13)
Roughly a third of the world's population feels the burden of some type of brain, spinal cord or peripheral nerve disease: dementia, depression, compulsion, infection, trauma. Understanding the need for investment, awareness and public policy advocacy in finding solutions for these afflictions, Zack Lynch founded the Neurotechnology Industry Organization in 2006, and serves as its executive director. In this interview with The Life Sciences Report, Lynch makes a bullish case for a growing industry and discusses how he proposes to increase funding for neuroscience from both private and public sources, thereby increasing options for patients and opportunities for investors. More >

The Best Small-Cap Biotech Picks for the Rest of 2013
Source: Scott Matusow, BioMedReports   (10/15/13)
"We have compiled five of our best end of year, and long-term small-cap developmental biopharma companies we feel have an excellent chance to be long-term 'multibaggers.'" More >

Backing Biotech Growth with Manufacturing Strength: Brian Wilson
Source: Daniel Levy of The Life Sciences Report  (10/10/13)
The focus of most small biotech and pharma companies is on discovery—looking for that next breakthrough in gene therapy, diagnostics, drug delivery and the like. While Bio-Wire.com's Brian Wilson has explored and written about the possibilities in these fields, he sees potential outside the traditional discovery sphere, in companies focused on low-profile tasks like contract manufacturing services. In this interview with The Life Sciences Report, Wilson names one of his favorites in that space, and discusses a pair of companies using contract manufacturing services to advance their own development strategies. More >

Biotech Companies Record Another Positive Quarter
Source: Peter Winter, BioWorld  (10/7/13)
"In all there were 27 public offering transactions generating $1.26 billion in the third quarter, with companies continuing to take advantage of their higher stock valuations and welcoming capital markets to raise funds for their operations." More >

Not All Stem Cells Are Created Equal: Vernon Bernardino
Source: Peter Byrne of The Life Sciences Report  (10/3/13)
Biotech companies are fiercely competing to create the newest and best miracle drugs using stem cell technologies. How can an investor spot the potentially victorious outliers amid the chaos of rival scientific claims? The failure rate of new product development in the only recently understood cell space is terrifying, but in this interview with The Life Sciences Report, analyst Vernon Bernardino of MLV & Co. reveals his formula for evaluating the strongest contenders. Bernardino also names five companies with products that may succeed in this new and competitive space. More >

3 Small-Cap Biotechnology Stocks Making Big Moves
Source: Tom Meyer, Wall St. Cheat Sheet  (10/1/13)
"Investors have seen a tremendous rally in the biotechnology industry. Many stocks have been participating in the rally, but there have been a few that are especially standing out because of performance and/or new announcements." More >

John McCamant Scans Under the Radar for Promising Biotechs
Source: Peter Byrne of The Life Sciences Report  (9/26/13)
With more than 25 years of experience in the biotech market, John McCamant, editor of the Medical Technology Stock Letter, understands how the seasons of the investment cycle can influence a company's value. But he sticks to the fundamentals: After all, a great pipeline and competent management can propel a biotech upward through blustery weather as well as blue sky. Find out how four companies fit his philosophy in this interview with The Life Sciences Report. More >

Muscling into the Nutritional Supplements Market: Brad Pyatt
Source: George S. Mack of The Life Sciences Report  (9/26/13)
Sports analogies are used way too often in business, but MusclePharm Corp.'s Founder, President and CEO Brad Pyatt has used his experience as a wide receiver in the National Football League to build a nutritional supplement business, employing leadership tools he learned from great coaches and players. In this interview with The Life Sciences Report, Pyatt talks about his young company's explosive growth, and how he expects to continue expanding both revenue and earnings to generate tremendous shareholder value. More >

In Vitro Diagnostics Growth to Spearhead Future of Medtech
Source: Elizabeth Cairns, EP Vantage  (9/23/13)
"The analysis of the top 20 sectors of the worldwide medical device market reveals that the IVD sector is expanding at a CAGR of 5.1%, outpacing the overall medtech market growth rate of 4.5%." More >

Provectus Pharmaceuticals Inc. and PV-10: Rose Bengal as a Novel Cancer Therapeutic
Source: Daniel Levy of The Life Sciences Report  (9/19/13)
Despite all of the advances in diagnosis and treatment, the family of diseases that falls under the umbrella of "cancer" still represents a significant unmet medical need. Consequently, research continues in the discovery and development of therapeutic agents with novel mechanisms of action, wider therapeutic indexes and lower overall toxicities. In this interview with The Life Sciences Report, Peter Culpepper, CFO and COO of Provectus Pharmaceuticals Inc., describes his company's innovative rose bengal formulation and its use as a cancer therapeutic. More >

Four Small-Cap Growth Names with Different Value Drivers: Keay Nakae
Source: George S. Mack of The Life Sciences Report  (9/19/13)
It's important to take the emotion out of investing. Keay Nakae, senior research analyst with Ascendiant Capital Markets, looks at micro- and small-cap biotech stocks from an engineer's perspective: It's all about the data. In this interview with The Life Sciences Report, Nakae reports on four companies with upcoming catalysts that potentially position them for significant growth—and the ability to grab investors' attention. More >

The Next Step in Killing Cancer
Source: Martin Biancuzzo, The Daily Reckoning  (9/16/13)
"After several years of trial and error, Olson and his team at the privately owned Seattle biotech firm Blaze Bioscience, have created something called 'tumor paint.' And the solution has come from the most unlikely of places. . .Scorpion venom." More >

Hidden Finds in Regenerative and Medical Technology: Jeff Cohen
Source: Peter Byrne of The Life Sciences Report  (9/12/13)
Ladenburg Thalmann & Co. Inc.'s Jeff Cohen regularly explores the frontiers of regenerative and medical technology looking for solid investment opportunities. In this interview with The Life Sciences Report, Cohen reveals promising finds in one of the world's fastest-growing business sectors. From robotics to skin grafts, Cohen knows his science and his market. More >

Griffin Securities' Keith Markey Gives Performance Reviews on Four Favorite Biotech Names
Source: Peter Byrne of The Life Sciences Report  (9/12/13)
As science director for Griffin Securities, Keith Markey knows his way around the advanced technologies of the most promising research in biotech. In this interview with The Life Sciences Report, Markey explains the science behind new developments in the antibiotic, diabetic and dermatological fields, highlighting ground-floor investment opportunities that investors will not want to miss. More >

Medtech Stock Update: Public Policy Forces Restructuring, M&A Activity
Source: Zacks Equity Research  (9/10/13)
"The Patient Protection and Affordable Care Act (PPACA), particularly the medical device excise tax, has taken a heavy toll on the medtech sector, hurting pricing decisions of the companies and subjecting them to tremendous margin pressure." More >

Digging Below the Surface of Neurotechnology: Casey Lynch
Source: George S. Mack of The Life Sciences Report  (9/5/13)
Neuroscience is about as complex as it gets. The central nervous system contains the brain and spinal cord, where hundreds of billions of neurons are located—and that doesn't include the peripheral nervous system. Casey Lynch, managing director of NeuroInsights, works to make sense of both the disease processes affecting the nervous system and potential therapies that could help patients and enrich investors. In this interview with The Life Sciences Report, Lynch brings some clarity to the complexity, and speaks frankly about the wild goose that some Alzheimer's disease investigators have been chasing. More >

Medical Conference Schedule Sept. 2013 through March 2014
Source: Michael King, JP Morgan  (9/5/13)
More >

Scientific Conferences Create Buzz and Move Biotech Stocks: Michael King
Source: George S. Mack of The Life Sciences Report  (9/5/13)
It's that time again. From Labor Day through the New Year, analysts jet off to conferences across the U.S. and Europe to hear data they've been waiting on for years. Michael King, managing director and senior biotechnology analyst at JMP Securities, has been at this game for almost two decades, and he has a firm grip on how data releases about molecules and their targets will affect the biotech stocks in his coverage. In this interview with The Life Sciences Report, King also names four growth companies making important advances in hematologic cancers. Just in time. More >

Breakthrough Therapy Designation Speeds Up Drug Approvals
Source: Patricia Dimond, Genetic Engineering and Biotechnology News  (9/4/13)
"The FDA's new development path is specifically designed for experimental agents that produce large and unprecedented treatment effects in early clinical trials. If a drug is designated a breakthrough therapy, the FDA says it will expedite the development and review of the drug." More >

Biotech Investor Realism with Andrew Fein
Source: Peter Byrne of The Life Sciences Report  (8/29/13)
Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory. And he doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops. He rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market. More >